Automate Your Wheel Strategy on CRSP
With Tiblio's Option Bot, you can configure your own wheel strategy including CRSP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRSP
- Rev/Share 0.4304
- Book/Share 21.2845
- PB 2.6432
- Debt/Equity 0.1199
- CurrentRatio 15.6355
- ROIC -0.2322
- MktCap 4858821762.0
- FreeCF/Share -3.5823
- PFCF -15.7826
- PE -12.5368
- Debt/Assets 0.1013
- DivYield 0
- ROE -0.2008
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CRSP | Evercore ISI | In-line | Outperform | $60 | $99 | Feb. 14, 2025 |
| Upgrade | CRSP | TD Cowen | Sell | Hold | -- | $35 | Feb. 12, 2025 |
| Initiation | CRSP | H.C. Wainwright | -- | Buy | -- | $65 | Feb. 3, 2025 |
News
Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Negative
CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Nearly 89% of Companies are Seeing Insider Selling, But these 3 are Seeing Substantial Buying
Published: July 22, 2025 by: 24/7 Wall Street
Sentiment: Negative
Corporate insiders have taken a sharply pessimistic turn – selling their companies' shares at the fastest rate in at least a decade.
Read More
The Big 3: ASML, GOOGL, CRSP
Published: July 15, 2025 by: Schwab Network
Sentiment: Neutral
ASML Holding (ASML) is "the machine that makes the machine," says Joe Tigay, referring to its importance in Nvidia's (NVDA) chipmaking process. While the stock closed the gap from April lows, he says outlook will continue to be key for the company.
Read More
Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)
Published: July 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Curing disease, as opposed to just masking symptoms, is a big deal. CRISPR Therapeutics aims to cure by editing problem genes. So CRSP is the future of medicine! This approach can be too futuristic for many tastes. That, plus questions about CRSP's ability to scale production and make treatments affordable, have been like a cloud over the stock. But in June, CRSP picked up some big-time expressions of support from Washington (including new HHS Secretary RFK Jr.). The stock responded with a strong rally.
Read More
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
Read More
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Biotech Stock for Options Bears to Target Right Now
Published: June 11, 2025 by: Schaeffers Research
Sentiment: Negative
Biotech stock Crispr Therapeutics Inc's (NASDAQ:CRSP) June rally appears to be coming to an end.
Read More
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
Read More
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
Read More
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
Read More
The Best Stocks to Invest $1,000 in Right Now
Published: June 03, 2025 by: The Motley Fool
Sentiment: Neutral
Are you just as afraid of a market pullback right now as you are of missing out on upside? If so, you're not alone.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
Read More
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
Published: May 16, 2025 by: MarketBeat
Sentiment: Positive
Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like something out of a science fiction novel, but it's here today and CRSPR Therapeutics AG NASDAQ: CRSP is leading the way.
Read More
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
CRSP's main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It's a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy's rollout has been slow due to its high cost, specialized centers, and lengthy required preconditioning. Still, CRSP will eventually receive 40% of Casgevy's profits through its partnership with VRTX.
Read More
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Negative
CRISPR Therapeutics' stock is down 20% since March, with ongoing high cash burn despite a robust $1.86 billion cash position. Casgevy's commercialization is slow, with over 65 treatment centers active but no recognized revenue yet, reflecting a complex administration process and gradual gene therapy adoption. Regulatory uncertainties under Dr. Vinay Prasad's FDA leadership could delay approvals, impacting CRISPR's gene and cell therapy timelines.
Read More
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates.
Read More
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Read More
2 Beaten-Down Stocks With Incredible Upside Potential
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
Read More
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.
Read More
About CRISPR Therapeutics AG (CRSP)
- IPO Date 2016-10-19
- Website https://www.crisprtx.com
- Industry Biotechnology
- CEO Samarth Kulkarni
- Employees 393